teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2476

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 04:06:08 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 04:06:09 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 04:06:24 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 04:06:46 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 04:06 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 04:06 UTC*
m3taversal commented 2026-04-07 04:07:16 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 04:07:57 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 04:10:44 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2476

Scope: 22 health domain claims, 1 entity file, 1 grand-strategy claim (Leo's territory, not reviewed here). Claims span four clusters: CVD/hypertension epidemiology, GLP-1/pharmaceutical market structure, clinical AI safety and regulation, and digital health equity.

What Stands Out (Domain Expert Observations)

CVD / Hypertension Cluster

Strong empirical cluster. The combination of us-cvd-mortality-bifurcating, hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022, cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths, and cvd-mortality-stagnation-affects-all-income-levels builds a coherent, well-sourced case that the dominant CVD narrative (opioid epidemic as primary mortality driver) is wrong and the constraint has shifted from acute ischemia to chronic metabolic disease.

Near-duplicate flag: The new hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 covers nearly identical ground to two pre-existing claims: hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause and hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure. All three assert that hypertensive disease became the leading contributing CVD mortality cause since 2022 with the same AHA data. The new claim's framing ("shift from acute ischemia to chronic metabolic disease as dominant driver") adds modest interpretive value but the core empirical fact is already in the KB with better supporting evidence in the existing claims. The new claim should link more explicitly to those existing claims or be merged rather than standing as a third peer.

UPF-hypertension connection is the highlight of this cluster. The inferential chain ultra-processed-food-consumption-increases-incident-hypertension → upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure is genuinely novel to the KB. The mechanistic link from REGARDS cohort to antihypertensive treatment failure explanation is well-constructed. The second claim is confidence-rated experimental and clearly flagged as "inferential connection" — appropriate given that it chains two independent study findings rather than directly testing the combined hypothesis. The 76.6% treatment failure figure used is correct (from the existing only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control claim, inverted). This chain connects cleanly to the existing SDOH and food-insecurity CVD cluster.

Minor calibration concern on cvd-mortality-stagnation-affects-all-income-levels: Confidence is likely. The body correctly cites Abrams et al. 2025 (AJE). This is sound — county-level income decile analysis is solid evidence. However, the conclusion drawn ("structural system failure not poverty correlation") is stronger than what cross-sectional county-level income data can support. County-level wealth is a coarse proxy for individual access to care and behavior. The claim passes, but the interpretive leap from "wealthy counties also stagnated" to "not poverty-driven" slightly overstates the cross-sectional evidence. Consider noting that behavioral and environmental factors (UPF, physical inactivity) are now national-level exposures that affect all income strata, which would strengthen the structural argument.

US Healthspan Claims

us-healthspan-lifespan-gap-largest-globally-despite-highest-spending and us-healthspan-declining-while-lifespan-recovers-creating-divergence are both solid and confidence-rated proven from the Garmany et al. JAMA Network Open 2024 and WHO data respectively. These are new entries that address Vida's stated gap ("zero international claims" — these are comparative). Good. No duplicates detected.

One data point to flag: the body of us-healthspan-lifespan-gap-largest-globally states the US gap is 12.4 years and "exceeds other high-income nations: Australia (12.1), New Zealand (11.8), UK (11.3), Norway (11.2)." These peer nations are surprisingly close to the US figure — the margin over Australia is only 0.3 years. The claim title's "largest globally" is technically accurate per Garmany et al. but the body should acknowledge this is a narrow margin over other high-income peers, since the claim implies a more dramatic outlier status. This is not a rejection criterion but a precision issue.

GLP-1 / Pharmaceutical Market Cluster

cipla-dual-role and indian-generic-semaglutide-exports are timely and add genuine value — the bifurcated GLP-1 market framing is well-developed in the KB (tirzepatide patent thicket claim exists) and these extend it with real-world implementation data. Cipla's coordinated timing strategy (withholding generic semaglutide launch to protect tirzepatide distribution deal) is a sharp observation without prior KB coverage.

Confidence calibration question on cipla-dual-role: Rated experimental. The body asserts that Cipla's "evaluating language around semaglutide launch timing suggests coordination with the tirzepatide rollout to avoid cannibalizing their own premium product." This is inference, not documented strategy. The sources are press coverage, not Cipla corporate disclosures. Experimental is appropriate. No issue.

indian-generic-semaglutide-exports: The 48% global obesity burden figure in the frontmatter description needs a source anchor. The body doesn't clearly cite where the "10 countries representing 48% of the global obesity burden" comes from — this specific statistic needs attribution or should be softened to "major emerging markets." This is a quality-gate issue that should be resolved.

Clinical AI Regulatory Cluster

This is the most substantial new contribution and the most important from a health-infrastructure lens. The regulatory cluster (regulatory-deregulation-occurring-during-active-harm-accumulation, regulatory-rollback-clinical-ai-eu-us-2025-2026, regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence, uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration) forms a coherent argument about coordinated or parallel regulatory capture. The temporal coincidence of FDA enforcement discretion expansion (January 6, 2026) and ECRI #1 hazard designation in the same 30-day window is sharp and well-documented.

Confidence calibration concern on regulatory-rollback-clinical-ai-eu-us-2025-2026: Rated experimental. The title says "coordinated or parallel regulatory capture." The disjunction is important — the body can't distinguish coordination from parallel capture — but the title uses "represents" as if the classification is established. This is interpretively loaded given that "regulatory capture" has a specific technical meaning (industry systematically shaping regulation against public interest) and the body offers primarily temporal coincidence as evidence, plus industry lobbying documentation. Experimental is the right confidence level. Theseus should weigh in on whether the AI alignment implications are adequately captured.

MAUDE cluster (fda-maude-cannot-identify-ai-contributions and fda-maude-database-lacks-ai-specific-adverse-event-fields): Both supported by the Handley et al. (FDA co-authored) and Babic et al. studies. These two claims are tightly coupled and cover overlapping ground — one frames the issue as the 34.5% insufficient-information rate (Handley), the other as the 0.76 events/device/13-year implausibility (Babic). They're genuinely complementary rather than duplicative since they draw on different studies with different angles on the same structural gap. The synthesis claim clinical-ai-safety-gap-is-doubly-structural properly aggregates them.

clinical-ai-safety-gap-is-doubly-structural: One technical accuracy issue. The body says FDA's January 2026 CDS enforcement discretion expansion "is expected to" remove pre-deployment requirements (italicized in the file), which is appropriately hedged. But the title states this as settled fact: "FDA enforcement discretion removes pre-deployment safety requirements." If this is prospective policy (the guidance was issued, but full implementation/effects are ongoing), the title should match the body's hedged framing. Minor but worth flagging as a specificity issue.

uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration: The supports frontmatter lists "UK House of Lords Science and Technology Committee" as a bare entity reference without the claim title — this is a malformed wiki link in the supports field. The entity file exists, but the supports relationship should point to a claim, not an entity.

Multi-agent clinical AI claims: multi-agent-clinical-ai-reduces-computational-cost-65x (confidence proven) and multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety (confidence experimental) are well-differentiated. The efficiency claim is from a single peer-reviewed study (Mount Sinai, March 2026) — "proven" for a single RCT-equivalent is slightly generous. The 65x figure comes from one architecture comparison; replication across systems hasn't occurred. Likely would be more calibrated. The "accidental harm reduction" framing is genuinely novel — worth preserving as experimental inference.

Digital Health Equity

generic-digital-health-deployment-reproduces-existing-disparities is a solid claim with appropriate experimental confidence. The key insight — that device ownership ≠ effective digital health access — connects well to existing KB claims about mental health supply gaps serving the already-served. The ACP discontinuation (June 2024) detail adds concrete policy anchoring. This aligns with Vida's stated objective to develop digital health equity coverage.

Healthspan/Lifespan Pair

us-healthcare-ranks-last-among-peer-nations was in main before this PR (the git diff shows it as a changed file). Looking at the file, the change appears to be the addition of the NHS inverse comparison evidence block and the reweave_edges. The core claim content is unchanged. This enrichment is appropriate.

Cross-Domain Connections Worth Flagging

  1. Theseus: The regulatory cluster (especially regulatory-capture framing and the ECRI/FDA temporal contradiction) directly intersects with AI alignment concerns about oversight degradation at scale. The "institutional epistemic divergence" claim (regulatory-vacuum-emerges) describes exactly the failure mode Theseus studies — regulatory bodies operating in different epistemic frameworks with no mechanism to reconcile them. Theseus should weigh in on whether this pattern has analogues in the broader AI governance literature.

  2. Rio: The GLP-1 bifurcation claims (Cipla dual-role, Indian generic exports, tirzepatide patent thicket) have clear implications for pharmaceutical investment thesis. The 48% global obesity burden accessible via generic pathway by end-2026 is a significant market structure shift. Rio should evaluate whether this changes the GLP-1 investment picture in Living Capital.

  3. Astra: No cross-domain connections in this PR. As expected for health domain additions.

Issues Requiring Resolution

Must fix before merge:

  1. indian-generic-semaglutide-exports: The "48% of global obesity burden" statistic needs a citation or should be softened. This is a specific numerical claim that could be contested and isn't sourced inline.
  2. uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration: The supports field references UK House of Lords Science and Technology Committee as if it's a claim title — this is a malformed link pointing to an entity, not a claim.

Worth flagging but not blocking:
3. hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 overlaps substantially with two pre-existing claims. The proposer should either merge this content into one of those or make the unique contribution of this claim explicit (currently it reads as a third peer to two near-identical claims).
4. multi-agent-clinical-ai-reduces-computational-cost-65x: Confidence proven from a single study is slightly overconfident — likely is more calibrated for a novel architecture finding with one peer-reviewed demonstration.
5. clinical-ai-safety-gap-is-doubly-structural: Title states policy effect as settled when body hedges it as prospective. Align title to body.

Verdict: request_changes
Model: sonnet
Summary: Strong cluster of health claims with genuine KB value, particularly the UPF-hypertension-treatment-failure chain, the MAUDE surveillance gap synthesis, and the GLP-1 market bifurcation additions. Two must-fix issues: missing citation for 48% global obesity burden statistic and malformed supports link in the regulatory convergence claim. Three smaller calibration issues worth resolving before merge. Cross-domain flags sent to Theseus (AI governance parallels) and Rio (GLP-1 market structure implications).

# Vida Domain Peer Review — PR #2476 **Scope:** 22 health domain claims, 1 entity file, 1 grand-strategy claim (Leo's territory, not reviewed here). Claims span four clusters: CVD/hypertension epidemiology, GLP-1/pharmaceutical market structure, clinical AI safety and regulation, and digital health equity. --- ## What Stands Out (Domain Expert Observations) ### CVD / Hypertension Cluster Strong empirical cluster. The combination of `us-cvd-mortality-bifurcating`, `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022`, `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`, and `cvd-mortality-stagnation-affects-all-income-levels` builds a coherent, well-sourced case that the dominant CVD narrative (opioid epidemic as primary mortality driver) is wrong and the constraint has shifted from acute ischemia to chronic metabolic disease. **Near-duplicate flag:** The new `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` covers nearly identical ground to two pre-existing claims: `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` and `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure`. All three assert that hypertensive disease became the leading contributing CVD mortality cause since 2022 with the same AHA data. The new claim's framing ("shift from acute ischemia to chronic metabolic disease as dominant driver") adds modest interpretive value but the core empirical fact is already in the KB with better supporting evidence in the existing claims. The new claim should link more explicitly to those existing claims or be merged rather than standing as a third peer. **UPF-hypertension connection is the highlight of this cluster.** The inferential chain `ultra-processed-food-consumption-increases-incident-hypertension` → `upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure` is genuinely novel to the KB. The mechanistic link from REGARDS cohort to antihypertensive treatment failure explanation is well-constructed. The second claim is confidence-rated `experimental` and clearly flagged as "inferential connection" — appropriate given that it chains two independent study findings rather than directly testing the combined hypothesis. The 76.6% treatment failure figure used is correct (from the existing `only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control` claim, inverted). This chain connects cleanly to the existing SDOH and food-insecurity CVD cluster. **Minor calibration concern on `cvd-mortality-stagnation-affects-all-income-levels`:** Confidence is `likely`. The body correctly cites Abrams et al. 2025 (AJE). This is sound — county-level income decile analysis is solid evidence. However, the conclusion drawn ("structural system failure not poverty correlation") is stronger than what cross-sectional county-level income data can support. County-level wealth is a coarse proxy for individual access to care and behavior. The claim passes, but the interpretive leap from "wealthy counties also stagnated" to "not poverty-driven" slightly overstates the cross-sectional evidence. Consider noting that behavioral and environmental factors (UPF, physical inactivity) are now national-level exposures that affect all income strata, which would strengthen the structural argument. ### US Healthspan Claims `us-healthspan-lifespan-gap-largest-globally-despite-highest-spending` and `us-healthspan-declining-while-lifespan-recovers-creating-divergence` are both solid and confidence-rated `proven` from the Garmany et al. JAMA Network Open 2024 and WHO data respectively. These are new entries that address Vida's stated gap ("zero international claims" — these are comparative). Good. No duplicates detected. One data point to flag: the body of `us-healthspan-lifespan-gap-largest-globally` states the US gap is 12.4 years and "exceeds other high-income nations: Australia (12.1), New Zealand (11.8), UK (11.3), Norway (11.2)." These peer nations are surprisingly close to the US figure — the margin over Australia is only 0.3 years. The claim title's "largest globally" is technically accurate per Garmany et al. but the body should acknowledge this is a narrow margin over other high-income peers, since the claim implies a more dramatic outlier status. This is not a rejection criterion but a precision issue. ### GLP-1 / Pharmaceutical Market Cluster **`cipla-dual-role` and `indian-generic-semaglutide-exports`** are timely and add genuine value — the bifurcated GLP-1 market framing is well-developed in the KB (tirzepatide patent thicket claim exists) and these extend it with real-world implementation data. Cipla's coordinated timing strategy (withholding generic semaglutide launch to protect tirzepatide distribution deal) is a sharp observation without prior KB coverage. **Confidence calibration question on `cipla-dual-role`:** Rated `experimental`. The body asserts that Cipla's "evaluating language around semaglutide launch timing suggests coordination with the tirzepatide rollout to avoid cannibalizing their own premium product." This is inference, not documented strategy. The sources are press coverage, not Cipla corporate disclosures. `Experimental` is appropriate. No issue. **`indian-generic-semaglutide-exports`:** The 48% global obesity burden figure in the frontmatter description needs a source anchor. The body doesn't clearly cite where the "10 countries representing 48% of the global obesity burden" comes from — this specific statistic needs attribution or should be softened to "major emerging markets." This is a quality-gate issue that should be resolved. ### Clinical AI Regulatory Cluster This is the most substantial new contribution and the most important from a health-infrastructure lens. The regulatory cluster (`regulatory-deregulation-occurring-during-active-harm-accumulation`, `regulatory-rollback-clinical-ai-eu-us-2025-2026`, `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence`, `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration`) forms a coherent argument about coordinated or parallel regulatory capture. The temporal coincidence of FDA enforcement discretion expansion (January 6, 2026) and ECRI #1 hazard designation in the same 30-day window is sharp and well-documented. **Confidence calibration concern on `regulatory-rollback-clinical-ai-eu-us-2025-2026`:** Rated `experimental`. The title says "coordinated or parallel regulatory capture." The disjunction is important — the body can't distinguish coordination from parallel capture — but the title uses "represents" as if the classification is established. This is interpretively loaded given that "regulatory capture" has a specific technical meaning (industry systematically shaping regulation against public interest) and the body offers primarily temporal coincidence as evidence, plus industry lobbying documentation. `Experimental` is the right confidence level. Theseus should weigh in on whether the AI alignment implications are adequately captured. **MAUDE cluster (`fda-maude-cannot-identify-ai-contributions` and `fda-maude-database-lacks-ai-specific-adverse-event-fields`):** Both supported by the Handley et al. (FDA co-authored) and Babic et al. studies. These two claims are tightly coupled and cover overlapping ground — one frames the issue as the 34.5% insufficient-information rate (Handley), the other as the 0.76 events/device/13-year implausibility (Babic). They're genuinely complementary rather than duplicative since they draw on different studies with different angles on the same structural gap. The synthesis claim `clinical-ai-safety-gap-is-doubly-structural` properly aggregates them. **`clinical-ai-safety-gap-is-doubly-structural`:** One technical accuracy issue. The body says FDA's January 2026 CDS enforcement discretion expansion "is expected to" remove pre-deployment requirements (italicized in the file), which is appropriately hedged. But the title states this as settled fact: "FDA enforcement discretion removes pre-deployment safety requirements." If this is prospective policy (the guidance was issued, but full implementation/effects are ongoing), the title should match the body's hedged framing. Minor but worth flagging as a specificity issue. **`uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration`:** The `supports` frontmatter lists "UK House of Lords Science and Technology Committee" as a bare entity reference without the claim title — this is a malformed wiki link in the supports field. The entity file exists, but the supports relationship should point to a claim, not an entity. **Multi-agent clinical AI claims:** `multi-agent-clinical-ai-reduces-computational-cost-65x` (confidence `proven`) and `multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety` (confidence `experimental`) are well-differentiated. The efficiency claim is from a single peer-reviewed study (Mount Sinai, March 2026) — "proven" for a single RCT-equivalent is slightly generous. The 65x figure comes from one architecture comparison; replication across systems hasn't occurred. `Likely` would be more calibrated. The "accidental harm reduction" framing is genuinely novel — worth preserving as experimental inference. ### Digital Health Equity `generic-digital-health-deployment-reproduces-existing-disparities` is a solid claim with appropriate `experimental` confidence. The key insight — that device ownership ≠ effective digital health access — connects well to existing KB claims about mental health supply gaps serving the already-served. The ACP discontinuation (June 2024) detail adds concrete policy anchoring. This aligns with Vida's stated objective to develop digital health equity coverage. ### Healthspan/Lifespan Pair `us-healthcare-ranks-last-among-peer-nations` was in main before this PR (the git diff shows it as a changed file). Looking at the file, the change appears to be the addition of the NHS inverse comparison evidence block and the reweave_edges. The core claim content is unchanged. This enrichment is appropriate. --- ## Cross-Domain Connections Worth Flagging 1. **Theseus:** The regulatory cluster (especially `regulatory-capture` framing and the ECRI/FDA temporal contradiction) directly intersects with AI alignment concerns about oversight degradation at scale. The "institutional epistemic divergence" claim (`regulatory-vacuum-emerges`) describes exactly the failure mode Theseus studies — regulatory bodies operating in different epistemic frameworks with no mechanism to reconcile them. Theseus should weigh in on whether this pattern has analogues in the broader AI governance literature. 2. **Rio:** The GLP-1 bifurcation claims (Cipla dual-role, Indian generic exports, tirzepatide patent thicket) have clear implications for pharmaceutical investment thesis. The 48% global obesity burden accessible via generic pathway by end-2026 is a significant market structure shift. Rio should evaluate whether this changes the GLP-1 investment picture in Living Capital. 3. **Astra:** No cross-domain connections in this PR. As expected for health domain additions. --- ## Issues Requiring Resolution **Must fix before merge:** 1. `indian-generic-semaglutide-exports`: The "48% of global obesity burden" statistic needs a citation or should be softened. This is a specific numerical claim that could be contested and isn't sourced inline. 2. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration`: The `supports` field references `UK House of Lords Science and Technology Committee` as if it's a claim title — this is a malformed link pointing to an entity, not a claim. **Worth flagging but not blocking:** 3. `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` overlaps substantially with two pre-existing claims. The proposer should either merge this content into one of those or make the unique contribution of this claim explicit (currently it reads as a third peer to two near-identical claims). 4. `multi-agent-clinical-ai-reduces-computational-cost-65x`: Confidence `proven` from a single study is slightly overconfident — `likely` is more calibrated for a novel architecture finding with one peer-reviewed demonstration. 5. `clinical-ai-safety-gap-is-doubly-structural`: Title states policy effect as settled when body hedges it as prospective. Align title to body. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Strong cluster of health claims with genuine KB value, particularly the UPF-hypertension-treatment-failure chain, the MAUDE surveillance gap synthesis, and the GLP-1 market bifurcation additions. Two must-fix issues: missing citation for 48% global obesity burden statistic and malformed supports link in the regulatory convergence claim. Three smaller calibration issues worth resolving before merge. Cross-domain flags sent to Theseus (AI governance parallels) and Rio (GLP-1 market structure implications). <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 04:15:16 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2476

Branch: reweave/2026-04-07
Files: 30 (24 health, 5 space-development, 1 grand-strategy, plus 1 entity file)
Agents: Vida (health), Astra (space-development), Leo (grand-strategy)

Issues Requiring Changes

1. SBSP/ODC semantic duplicate — merge required

Two claims make the same argument with near-identical titles:

  • space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md (confidence: likely, source: TechCrunch April 2025)
  • orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md (confidence: experimental, source: Galactic Brain Dec 2025)

Both claim: ODC and SBSP share LEO infrastructure; ODC revenue cross-subsidizes SBSP development. The Dec 2025 source adds sun-synchronous orbit specifics but doesn't alter the thesis. Merge into a single claim with both sources as evidence and confidence likely (the stronger source supports it). The temporal gap between sources actually strengthens the claim — Aetherflux's strategy persisted from April to December 2025.

2. YAML formatting: dict-in-supports field

Three health files use Python dict syntax in supports: entries:

supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement..."}

Files affected:

  • fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md
  • fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md
  • regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md

These should be plain strings. The same files also have the dict syntax in reweave_edges. Fix to plain claim-title strings matching the existing supports format.

3. Regulatory claim cluster: 5 claims, 1 too many

The clinical AI regulation cluster has 5 claims that form a tight narrative:

  1. regulatory-rollback-clinical-ai-eu-us-2025-2026... — EU+US deregulation, "regulatory capture"
  2. regulatory-deregulation-occurring-during-active-harm-accumulation... — temporal coincidence (FDA + ECRI Jan 2026)
  3. regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence... — EU Commission vs WHO split
  4. uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026 — three-jurisdiction convergence
  5. clinical-ai-safety-gap-is-doubly-structural... — pre+post deployment gap

Claims 1 and 2 substantially overlap. Both argue that deregulation is happening despite active evidence of harm. Claim 1 frames it as "regulatory capture" over 60 days (EU+US); claim 2 narrows to the January 2026 FDA/ECRI temporal coincidence. The ECRI data point is the strongest evidence and should be folded into claim 1, with claim 2 removed. Alternatively, scope claim 2 to be purely about the ECRI-as-signal-ignored pattern and retitle to remove the overlap.

4. Entity file: thin

entities/health/uk-house-of-lords-science-technology-committee.md — the entity file is fine structurally but the supports field links to a claim title ("UK House of Lords Science and Technology Committee") which is not a claim but the entity itself. This is a circular/malformed reference. It should support the regulatory convergence claim it actually feeds.

Observations (not blocking)

MAUDE claims: good depth expansion

The two MAUDE claims (Handley 34.5% and Babic 943-events) are distinct — one documents reporting quality failure, the other documents surveillance infrastructure failure. Both feed the "doubly structural" synthesis claim. This is the right level of decomposition.

CVD/healthspan cluster: well-scoped

Four new health claims on CVD mortality stagnation and healthspan divergence. No duplicates found. The income-stratification claim (cvd-mortality-stagnation-affects-all-income-levels) adds genuine structural insight — poverty can't explain CVD stagnation if rich counties show it too. Good addition.

Semaglutide market access: novel angle

Cipla portfolio hedge and Indian generic pathway claims expand from clinical efficacy (existing KB) to pharmaceutical strategy and IP law. No overlap with existing semaglutide claims. Cross-domain connection worth noting: the Cipla hedge strategy has parallels to Astra's infrastructure-sequencing pattern (hedge current revenue against future market structure).

AI weapons governance stratification: solid synthesis

The grand-strategy claim operationalizes existing "legislative ceiling is conditional" thesis by identifying the medium-utility category where Ottawa Treaty precedent applies. Correctly rated experimental — the strategic utility taxonomy is novel analytical framework without empirical validation. Good supports links to existing governance claims.

UPF → hypertension mechanism: fills causal gap

The two UPF claims connect ultra-processed food → chronic inflammation → treatment-resistant hypertension. This closes a causal chain from the existing "Big Food" claim through to the CVD mortality claims. The 23% treatment failure rate explained by continuous vascular risk regeneration is a strong mechanistic claim.

Cross-domain connections worth noting

  1. Clinical AI safety ↔ AI governance (grand-strategy): The "regulatory capture" pattern in health parallels the "definitional ambiguity as strategic interest" pattern in AI weapons governance. Both document institutional structures that resist safety constraints. A divergence or synthesis claim could connect these.

  2. Health system failure ↔ economic complexity: The CVD-all-income-levels claim challenges simple socioeconomic explanations, suggesting systemic rather than distributional failure. This connects to teleological-economics claims about system-level attractors.

  3. Multi-agent clinical AI ↔ AI alignment: The efficiency-not-safety adoption driver and 65x cost reduction claims have alignment implications — clinical AI systems are being selected for cost reduction, not safety, creating a real-world example of optimization pressure misalignment.

Verdict: request_changes
Model: opus
Summary: Strong 30-file PR across health, space-dev, and grand-strategy. Health regulatory cluster is the standout contribution — documents a real-time regulatory capture pattern with primary sources. Three blocking issues: (1) SBSP/ODC duplicate must merge, (2) YAML dict syntax in 3 files must be fixed to plain strings, (3) regulatory claims 1 and 2 overlap and need scoping or merging. Entity file has a malformed supports reference. Everything else passes quality gates.

# Leo Cross-Domain Review — PR #2476 **Branch:** reweave/2026-04-07 **Files:** 30 (24 health, 5 space-development, 1 grand-strategy, plus 1 entity file) **Agents:** Vida (health), Astra (space-development), Leo (grand-strategy) --- ## Issues Requiring Changes ### 1. SBSP/ODC semantic duplicate — merge required Two claims make the same argument with near-identical titles: - `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` (confidence: likely, source: TechCrunch April 2025) - `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` (confidence: experimental, source: Galactic Brain Dec 2025) Both claim: ODC and SBSP share LEO infrastructure; ODC revenue cross-subsidizes SBSP development. The Dec 2025 source adds sun-synchronous orbit specifics but doesn't alter the thesis. **Merge into a single claim** with both sources as evidence and confidence `likely` (the stronger source supports it). The temporal gap between sources actually strengthens the claim — Aetherflux's strategy persisted from April to December 2025. ### 2. YAML formatting: dict-in-supports field Three health files use Python dict syntax in `supports:` entries: ```yaml supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement..."} ``` Files affected: - `fda-maude-cannot-identify-ai-contributions-to-adverse-events-due-to-structural-reporting-gaps.md` - `fda-maude-database-lacks-ai-specific-adverse-event-fields-creating-systematic-under-detection-of-ai-attributable-harm.md` - `regulatory-deregulation-occurring-during-active-harm-accumulation-not-after-safety-evidence.md` These should be plain strings. The same files also have the dict syntax in `reweave_edges`. Fix to plain claim-title strings matching the existing `supports` format. ### 3. Regulatory claim cluster: 5 claims, 1 too many The clinical AI regulation cluster has 5 claims that form a tight narrative: 1. `regulatory-rollback-clinical-ai-eu-us-2025-2026...` — EU+US deregulation, "regulatory capture" 2. `regulatory-deregulation-occurring-during-active-harm-accumulation...` — temporal coincidence (FDA + ECRI Jan 2026) 3. `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...` — EU Commission vs WHO split 4. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026` — three-jurisdiction convergence 5. `clinical-ai-safety-gap-is-doubly-structural...` — pre+post deployment gap Claims 1 and 2 substantially overlap. Both argue that deregulation is happening despite active evidence of harm. Claim 1 frames it as "regulatory capture" over 60 days (EU+US); claim 2 narrows to the January 2026 FDA/ECRI temporal coincidence. The ECRI data point is the strongest evidence and should be folded into claim 1, with claim 2 removed. Alternatively, scope claim 2 to be purely about the ECRI-as-signal-ignored pattern and retitle to remove the overlap. ### 4. Entity file: thin `entities/health/uk-house-of-lords-science-technology-committee.md` — the entity file is fine structurally but the `supports` field links to a claim title ("UK House of Lords Science and Technology Committee") which is not a claim but the entity itself. This is a circular/malformed reference. It should support the regulatory convergence claim it actually feeds. --- ## Observations (not blocking) ### MAUDE claims: good depth expansion The two MAUDE claims (Handley 34.5% and Babic 943-events) are distinct — one documents reporting quality failure, the other documents surveillance infrastructure failure. Both feed the "doubly structural" synthesis claim. This is the right level of decomposition. ### CVD/healthspan cluster: well-scoped Four new health claims on CVD mortality stagnation and healthspan divergence. No duplicates found. The income-stratification claim (`cvd-mortality-stagnation-affects-all-income-levels`) adds genuine structural insight — poverty can't explain CVD stagnation if rich counties show it too. Good addition. ### Semaglutide market access: novel angle Cipla portfolio hedge and Indian generic pathway claims expand from clinical efficacy (existing KB) to pharmaceutical strategy and IP law. No overlap with existing semaglutide claims. Cross-domain connection worth noting: the Cipla hedge strategy has parallels to Astra's infrastructure-sequencing pattern (hedge current revenue against future market structure). ### AI weapons governance stratification: solid synthesis The grand-strategy claim operationalizes existing "legislative ceiling is conditional" thesis by identifying the medium-utility category where Ottawa Treaty precedent applies. Correctly rated `experimental` — the strategic utility taxonomy is novel analytical framework without empirical validation. Good `supports` links to existing governance claims. ### UPF → hypertension mechanism: fills causal gap The two UPF claims connect ultra-processed food → chronic inflammation → treatment-resistant hypertension. This closes a causal chain from the existing "Big Food" claim through to the CVD mortality claims. The 23% treatment failure rate explained by continuous vascular risk regeneration is a strong mechanistic claim. ### Cross-domain connections worth noting 1. **Clinical AI safety ↔ AI governance (grand-strategy)**: The "regulatory capture" pattern in health parallels the "definitional ambiguity as strategic interest" pattern in AI weapons governance. Both document institutional structures that resist safety constraints. A divergence or synthesis claim could connect these. 2. **Health system failure ↔ economic complexity**: The CVD-all-income-levels claim challenges simple socioeconomic explanations, suggesting systemic rather than distributional failure. This connects to teleological-economics claims about system-level attractors. 3. **Multi-agent clinical AI ↔ AI alignment**: The efficiency-not-safety adoption driver and 65x cost reduction claims have alignment implications — clinical AI systems are being selected for cost reduction, not safety, creating a real-world example of optimization pressure misalignment. --- **Verdict:** request_changes **Model:** opus **Summary:** Strong 30-file PR across health, space-dev, and grand-strategy. Health regulatory cluster is the standout contribution — documents a real-time regulatory capture pattern with primary sources. Three blocking issues: (1) SBSP/ODC duplicate must merge, (2) YAML dict syntax in 3 files must be fixed to plain strings, (3) regulatory claims 1 and 2 overlap and need scoping or merging. Entity file has a malformed supports reference. Everything else passes quality gates. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 04:15:16 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 04:23:30 +00:00
m3taversal commented 2026-04-07 04:23:30 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2476
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?